Magnus Aurivillius

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.3K citations

Asthma, Rheumatology, Placebo-controlled Phase 3 +9

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez et al. · The Lancet · 2016 · 1.3K citations

Asthma, Allergy, Placebo-controlled Phase 3 +10

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson et al. · New England Journal of Medicine · 2020 · 635 citations · Full text

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

Gary T. Ferguson, Klaus F. Rabe, Fernando J. Martínez et al. · The Lancet Respiratory Medicine · 2018 · 388 citations

Translational Medicine, Pulmonary Care, Advanced Lung Disease +8

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 244 citations · Full text